Saturday, February 11, 2012
press release: The Clearity Foundation - Molecular profiling reveals differences between primary and recurrent ovarian cancers
Analysis of tumor specimens uncovers changes in biomarker expression that may have implications for therapy selection for women with recurrent ovarian cancer
"These results demonstrate the dynamic genetic changes in ovarian cancers between diagnosis and recurrence. While the expression of these and other candidate response biomarkers should be evaluated in larger studies to better understand the clinical utility of profiling recurrent tumor specimens, this report highlights our urgent need to individualize our treatment approaches in order to improve ovarian cancer survival," says Dr. Karlan, Director of the Cedars-Sinai Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute and a renowned expert in the field of gynecologic oncology.".....Ovarian cancers are very different from patient to patient, which means they are likely to respond differently to FDA-approved and investigational drugs. By identifying the alterations in each tumor's information pathways, molecular profiling enables the individualization of a patient's treatment by matching those tumor alterations with one or more drugs. The Clearity Foundation has developed a process for generating this personalized diagnostic information using commercially-available molecular profiling technologies and then analyzing the results using its Diane Barton Database."
What’s All the Fuss about Conflict of Interest in Medical Care? Conflicts of Interest in Medical Care | The Medical Professionalism Blog (re: NY Times article "I Disclose....Nothing"
What’s All the Fuss about Conflict of Interest in Medical Care?
Written by Daniel Wolfson on February 10, 2012"A couple of weeks ago, the New York Times published a story entitled I Disclose…Nothing by Elisabeth Rosenthal. The premise of the article dealt with conflicts of interests in several professions, including those in medicine. It got me thinking about whether or not the concept of disclosure can successfully manage conflicts of interest in medicine as much as people expect it to.
The conclusion I came up with, in short, was no....."
Blogger's Note: the 'timeline' section includes stats on ovarian cancer
Relentless Progress: ASCO Responds
ALLEN S. LICHTER
American Society of Clinical Oncology, Alexandria, Virginia, USA
Dr. Beatty’s thoughtful piece  brings up a number of important
points. Progress against cancer has been relentless. To
summarize these advances, the American Society of Clinical
Oncology (ASCO) has created a website:
It’s a summary of important milestones in each cancer and
each treatment modality, concentrating on the 40 years since
the signing of the National Cancer Act in 1971......